Search

Displaying results 2711 - 2720 of 10000 in total
  1. Pathway

    Lysinuric Protein Intolerance

    smpdb.ca/view/SMP0000197
    Disease

    Lysinuric protein intolerance (Hyperdibasic aminoaciduria II; Dibasic aminoaciduria II; Hyperdibasic aminoaciduria II; LPI), also called hyperdibasic aminoaciduria type 2 or familial protein intolerance, is an autosomal recessive metabol...

    Drugs: Cysteine · Potassium cation · Urea
    Enzymes: Y+L amino acid transporter 2, Y+L amino acid transporter 1
  2. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    (mu) - and δ (delta) -opioid receptors. … The fruits contain mixture of iridoids, flavonoids and compounds in leaves and flowers that structurally resemble sex hormones.

    Categories: Genito Urinary System and Sex Hormones
  3. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  4. Drug

    Davanat

    go.drugbank.com/drugs/DB15311
    Investigational

    Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).

  5. Drug

    Ziconotide

    go.drugbank.com/drugs/DB06283
    ApprovedInvestigational

    Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds. … [L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835]

    Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor Antagonists
  6. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … hormone (GH) and decreases the production of growth-promoting insulin-like growth factor 1 (IGF-1).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    Elismetrep

    go.drugbank.com/drugs/DB15287
    Investigational

    Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).

  8. Drug

    Patritumab deruxtecan

    go.drugbank.com/drugs/DB21996
    Investigational

    Patritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).

  9. Pathway

    Chlorothiazide Action Pathway

    smpdb.ca/view/SMP0000078
    Drug action

    Chlorothiazide (also known as Diuril) is an organic compound that used for diuretic. It can inhibit the solute carrier family 12 member 3 (also known as sodium-chloride symporter) in the nephron to prevent water reabsorption. Solute carr...

    Drugs: Cysteine · Chlorothiazide · Potassium cation · Urea
    Enzymes: Y+L amino acid transporter 2, Y+L amino acid transporter 1
  10. Pathway

    Bumetanide Action Pathway

    smpdb.ca/view/SMP0000088
    Drug action

    In the nephron, the think ascending limb reabsorbs 25% of sodium and is a good target for diuretics.

    Drugs: Cysteine · Bumetanide · Potassium cation · Urea
    Enzymes: Y+L amino acid transporter 2, Y+L amino acid transporter 1